Eric R. Gamazon, PhD, MS
Eric R. Gamazon, PhD, MS is a member of the faculty of the Division of Genetic Medicine at Vanderbilt University Medical Center. An elected Fellow of the Royal Society of Biology (2018), he is a Life Member of Clare Hall, University of Cambridge and holds an honorary scientist post in the university's MRC Epidemiology Unit. Trained in Biostatistics (Statistical Genetics), Mathematics, and Genomics at the University of Chicago and University of Amsterdam, he has authored or co-authored 150 peer-reviewed publications. He is on the Editorial Board of the journal Circulation Research, the official journal of the American Heart Association.
He is interested in what can be learned from DNA sequence and multi-omics data about disease mechanism, therapeutic intervention, molecular evolution, and genome function. An ongoing project involves understanding the effect of genetic variation on gene regulation across tissues and cell types to gain insights into disease mechanisms and therapeutic targets. He utilizes large-scale DNA biobank data linked to electronic health records, along with data science and computation, to identify genes involved in human health and disease in diverse populations, to discover novel biomarkers, and to enable a comprehensive systems view of the disease phenome.
He is part of the GTEx Consortium and the T2D-GENES Consortium. He was also a member of the International Warfarin Pharmacogenetics Consortium GWAS team.
Current research interests in complex traits genetics include characterizing the genetic architecture of hematopoietic diseases, including Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML). He is developing functional genomics resources for probing molecular mechanisms underlying hematopoiesis and hematologic disorders.
Ongoing research also includes modeling the transcriptional regulatory programs in the brain, in collaboration with human geneticists, neuroscientists, and evolutionary biologists. This work has obvious relevance to understanding the molecular basis of neuropsychiatric and neurodegenerative disorders.
He is a recipient of the inaugural Genomic Innovator Award from the National Institutes of Health (NIH).